J. F. Carlquist (1, 2), S. Knight (1, 3), B. D. Horne (1, 3), J. A. Huntinghouse (1), J. S. Rollo (1), J. B. Muhlestein (1, 2), H. May (1), J. L. Anderson (2, 1)
(1) Intermountain Heart Institute, Intermountain Healthcare, Murray, Utah, USA; (2) Department of Internal Medicine, Cardiology Division, University of Utah School of Medicine, Salt Lake City, Utah, USA; (3) Department of Internal Medicine, Genetic Epidemiology Division, University of Utah School of Medicine, Salt Lake City, Utah, USA
Long-term (at least one year) dual anti-platelet therapy incorporating aspirin and clopidogrel is currently recommended following percutaneous coronary intervention with placement of a drug-eluting stent (DES). Genetic variants in both the ABCB1 and CYP2C19 genes have been associated with cardiovascular events among patients on clopidogrel. We examined the concurrent contribution of the CYP2C19 *2 and *17 alleles and the ABCB1 3435 alleles to one-year clinical risk among patients (n=1,034 on clopidogrel therapy following the placement of a DES. For CYP2C19*2, event rates were 8.4%, 10.9% and 44.4% for patients with 0, 1 and 2 *2 alleles, respectively (p=0.016). ABCB1 3435 was not associated with events in univariate analysis. However, 72% of patients with a *2 variant also possessed the ABCB1 3435 C allele; among these patients (*2/C genotype) the event rate for myocardial infarction (MI) was 14.2% vs. 6.9% for those lacking both *2 and C alleles (p=0.027) and for MI/death, 16.9% vs. 9.6% (p=0.046). Overall for all genotypes, the presence of the gain-of-function (protective) *17 allele significantly reduced the one-year rate of MI from 11.1% to 7.0% (p=0.045) and trended to reduce the combined rate of MI/death from 13.8% to 10.5% (p=0.182). In conclusion, the ABCB1 3435 locus and the *2 allele combine to impart a significant trend toward increased risk. This trend was largely reversed by the simultaneous carriage of one or two *17 alleles. These findings suggest that assessment of a combined genotype may improve risk assessment.
Pharmacogenetics, cardiovascular risk, Antiplatelet agents
María González-Díez, Cristina Rodríguez, Lina Badimon, José Martínez-González
Thromb Haemost 2008 100 1: 119-126
Kenneth J. Clemetson, Jeannine M. Clemetson
Thromb Haemost 2008 99 3: 473-479
Andreas E. May, Tobias Geisler, Meinrad Gawaz
Thromb Haemost 2008 99 3: 487-493
Patients receiving oral anticoagulants should be carefully managed to minimize the risk of bleeding...
Acquired haemophilia A (AHA) is a rare but often severe bleeding disorder caused by ...
Section III " Vitamin K antagonists in heart disease: Current status and perspectives" of...